{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT04476901",
      "OrgStudyIdInfo": {
        "OrgStudyId": "20200566"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "CDMRP-PR191597",
            "SecondaryIdType": "Other Grant/Funding Number",
            "SecondaryIdDomain": "US Department of Defense"
          },
          {
            "SecondaryId": "20-02-134",
            "SecondaryIdType": "Other Identifier",
            "SecondaryIdDomain": "BRANY IRB"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "University of Miami",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Transendocardial Injection of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy",
      "OfficialTitle": "A Phase IIB Randomized, Placebo-Controlled, Multicenter Study of the Comparative Efficacy and Safety of Transendocardial Injection of Allogeneic-MSC Versus Placebo in Patients With Non- Ischemic Dilated Cardiomyopathy",
      "Acronym": "DCMII"
    },
    "StatusModule": {
      "StatusVerifiedDate": "January 2022",
      "OverallStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "May 7, 2021",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 2024",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 2024",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "July 15, 2020",
      "StudyFirstSubmitQCDate": "July 15, 2020",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "July 20, 2020",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "January 5, 2022",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "January 10, 2022",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor-Investigator",
        "ResponsiblePartyInvestigatorFullName": "Joshua M Hare",
        "ResponsiblePartyInvestigatorTitle": "Principal Investigator",
        "ResponsiblePartyInvestigatorAffiliation": "University of Miami"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Joshua M Hare",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "United States Department of Defense",
            "CollaboratorClass": "FED"
          },
          {
            "CollaboratorName": "The University of Texas Health Science Center, Houston",
            "CollaboratorClass": "OTHER"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "Yes",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called human allogeneic mesenchymal stem cell therapy."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Non-ischemic Dilated Cardiomyopathy"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Allogeneic mesenchymal stem cells",
          "Bone marrow-derived mesenchymal stem cells"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Quadruple",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Care Provider",
              "Investigator",
              "Outcomes Assessor"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "136",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Genotype A administered with placebo Group",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "Participants whose blood genotyping resulted with Genotype A (absence of any variant/ presence of benign variant) and randomized to the placebo group will receive the placebo intervention.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Other: Placebo"
              ]
            }
          },
          {
            "ArmGroupLabel": "Genotype A administered with hMSC Group",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Participants whose blood genotyping resulted with Genotype A (absence of any variant/ presence of benign variant) and randomized to the treatment group will receive the hMSC intervention.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: allogeneic human mesenchymal stem cells (hMSCs)"
              ]
            }
          },
          {
            "ArmGroupLabel": "Genotype B administered with placebo Group",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "Participants whose blood genotyping resulted with Genotype B (variants of uncertain significance) and randomized to the placebo group will receive the placebo intervention.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Other: Placebo"
              ]
            }
          },
          {
            "ArmGroupLabel": "Genotype B administered with hMSC Group",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Participants whose blood genotyping resulted with Genotype B (variants of uncertain significance) and randomized to the treatment group will receive the hMSC intervention.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: allogeneic human mesenchymal stem cells (hMSCs)"
              ]
            }
          },
          {
            "ArmGroupLabel": "Genotype C administered with placebo Group",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "Participants whose blood genotyping resulted with Genotype C (pathogenic or likely pathogenic variants) and randomized to the placebo group will receive the placebo intervention.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Other: Placebo"
              ]
            }
          },
          {
            "ArmGroupLabel": "Genotype C administered with hMSC Group",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Participants whose blood genotyping resulted with Genotype C (pathogenic or likely pathogenic variants) and randomized to the treatment group will receive the hMSC intervention.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: allogeneic human mesenchymal stem cells (hMSCs)"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "allogeneic human mesenchymal stem cells (hMSCs)",
            "InterventionDescription": "allo-hMSCs, 16-20 million cells/ml delivered at a dose of 0.5 ml/ injection x 10 injections for a total of 80-100 million allo-hMSCs",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Genotype A administered with hMSC Group",
                "Genotype B administered with hMSC Group",
                "Genotype C administered with hMSC Group"
              ]
            }
          },
          {
            "InterventionType": "Other",
            "InterventionName": "Placebo",
            "InterventionDescription": "Placebo will be administered as injections of plasmalyte A supplemented with 1% of 25% human serum albumin (HSA). 0.5 ml/ injection x 10 injections",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Genotype A administered with placebo Group",
                "Genotype B administered with placebo Group",
                "Genotype C administered with placebo Group"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Change in LVEF",
            "PrimaryOutcomeDescription": "Change in Left Ventricular Ejection Fraction (LVEF) as assessed via cardiac Magnetic Resonance Imaging (MRI)",
            "PrimaryOutcomeTimeFrame": "Baseline, 12 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Change in global ventricular strain",
            "SecondaryOutcomeDescription": "Change in global ventricular strain as assessed via cardiac Harmonic Phase (HARP) MRI",
            "SecondaryOutcomeTimeFrame": "Baseline, 12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Change in left regional strain",
            "SecondaryOutcomeDescription": "Change in regional ventricular strain as assessed via cardiac HARP MRI",
            "SecondaryOutcomeTimeFrame": "Baseline, 12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Left ventricular function concordance",
            "SecondaryOutcomeDescription": "The left ventricular function concordance will be measured as the Number of individuals who experienced an increase in left ventricular ejection fraction (LVEF) and a simultaneous decrease in both left ventricular end systolic volume index (LVESVI) and left ventricular end diastolic volume index (LVEDVI)",
            "SecondaryOutcomeTimeFrame": "12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Change in LVEDVI",
            "SecondaryOutcomeDescription": "Change in left ventricular end diastolic index (LVEDVI) as assessed via cardiac MRI",
            "SecondaryOutcomeTimeFrame": "Baseline, 12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Change in LVESVI",
            "SecondaryOutcomeDescription": "Change in left ventricular end systolic index (LVESVI) as assessed via cardiac MRI",
            "SecondaryOutcomeTimeFrame": "Baseline, 12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Change in Maximal oxygen consumption (peak VO2)",
            "SecondaryOutcomeDescription": "Change in maximal oxygen consumption (peak VO2) as assessed via treadmill",
            "SecondaryOutcomeTimeFrame": "Baseline, 12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Change in Exercise tolerance",
            "SecondaryOutcomeDescription": "Change in exercise tolerance as assessed as the distance covered via the six-minute walk test",
            "SecondaryOutcomeTimeFrame": "Baseline, 12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Change in Minnesota Living with Heart Failure Questionnaire (MLHFQ) Score",
            "SecondaryOutcomeDescription": "Minnesota Living with Heart Failure Questionnaire (MLHFQ) is a 21-item questionnaire with a total score ranging from 0 to 105 with lower scores indicative of better outcome.",
            "SecondaryOutcomeTimeFrame": "Baseline, 12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Change in New York Heart Association (NYHA) Class",
            "SecondaryOutcomeDescription": "NYHA Classifications of heart failure are as follows: Class I (no limitations); Class II (mild symptoms); Class III (marked limitations); Class IV (Severe limitations)",
            "SecondaryOutcomeTimeFrame": "Baseline, 12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Percent change in flow mediated diameter",
            "SecondaryOutcomeDescription": "Change in endothelial function will be reported as the percent change in flow mediated diameter assessed via flow mediated dilation (FMD).",
            "SecondaryOutcomeTimeFrame": "Baseline, 12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Change in EPC-CFU",
            "SecondaryOutcomeDescription": "Change in endothelial function will be reported as the change in Endothelial Progenitor Cell Colony Forming Unit (EPC-CFU) assessed via blood sample assay",
            "SecondaryOutcomeTimeFrame": "Baseline, 12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Change in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)",
            "SecondaryOutcomeDescription": "Change in NT-proBNP as assessed via blooddraw",
            "SecondaryOutcomeTimeFrame": "Baseline, 12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Change in cytokines",
            "SecondaryOutcomeDescription": "Change in NT-proBNP as assessed via blooddraw",
            "SecondaryOutcomeTimeFrame": "Baseline, 12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Incidence of MACE",
            "SecondaryOutcomeDescription": "Safety will be reported as the incidence of Major Adverse Cardiac Events (MACE) assessed by treating physician",
            "SecondaryOutcomeTimeFrame": "12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Incidence of TE-SAEs",
            "SecondaryOutcomeDescription": "Safety will be reported as the incidence of Treatment Emergent Serious Adverse Events (TE-SAEs) assessed by treating physician",
            "SecondaryOutcomeTimeFrame": "Day 30"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\nMen and women aged 18 to 80 years (inclusive) at the time of signing the informed consent form.\nDiagnosis of NIDCM with left ventricular ejection fraction ≤45%. Note: a left ventricular end diastolic diameter (LVEDD) ≥ 5.6cm in male subjects, an LVEDD of ≥ 5.4cm in female subjects, or left ventricular end diastolic volume index ≥ 125 mL/m2 (in either sex).\nAppropriate guideline-directed optimal medical therapy for non-ischemic cardiomyopathy. At a minimum, subjects must be on beta blockers and angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) or Angiotensin Receptor Neprilysin Inhibitors (ARNI) or have appropriate medical indication precluding use of one or both of these agents. Subjects must be on a stable regimen for at least 30 days prior to the procedure. Dose titration is allowed.\nBe a candidate for cardiac catheterization.\nBe willing to undergo DNA test.\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\nBe eligible for or require standard-of-care surgical or percutaneous intervention for the treatment of non-ischemic dilated cardiomyopathy\nClinical manifestation of coronary artery disease (CAD) (e.g., chest pain and concomitant clinical findings such as electrocardiogram changes suggestive of coronary ischemia, myocardial infarction) or evidence of endocardial or transmural scar on cardiac MRI suggestive of undiagnosed CAD or history of percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG). Be indicated for or require coronary artery revascularization\nDocumented presence of epicardial stenosis of 70% or greater in one or more major epicardial coronary arteries\nValvular heart disease including 1) aortic valve prosthesis, mechanical mitral valve, and mitral valve clip; 2) severe aortic valve insufficiency/regurgitation within 12 months of consent\nAortic stenosis with valve area ≤ 1.5cm2\nCardiomyopathy due to acute Post-partum (within 6 months), Non-compaction, or Hypertrophic cardiomyopathy\nCardiomyopathy due to any known toxin (e.g amyloid, anthracycline)\nQTc interval > 550 ms on baseline electrocardiogram (ECG) (note: QTc interval is the interval between the start of the Q wave and the end of the T wave in the heart's electrical cycle)\nAutomated Implantable Cardioverter Defibrillator (AICD) appropriate firing or anti tachycardia pacing for ventricular tachycardia or ventricular fibrillation within 30 days prior to consent\nHave an estimated baseline glomerular filtration rate below the clinical site's institutional cutoff\nA hematologic abnormality during baseline testing as evidenced by hemoglobin < 9 g/dl; hematocrit < 30%; absolute neutrophil count < 2,000 or total WBC count more than 2 times upper limit of normal; or platelet values < 100,000/ul\nHave liver dysfunction, as evidenced by enzymes Aspartate Transaminase Enzyme (AST) and Alanine Aminotransferase Enzyme (ALT) greater than three times the ULN\nHave a bleeding diathesis or coagulopathy (International Normalised Ratio (INR) > 1.5), cannot be withdrawn from anticoagulation therapy, or will refuse blood transfusions\nBe a solid organ transplant recipient. This does not include prior cell based therapy (>12 months prior to enrollment), bone, skin, ligament, tendon or corneal grafting.\nHave a history of organ or cell transplant rejection\nHave a clinical history of malignancy within the past 2 years (i.e., subjects with prior malignancy must be disease free for 2 years), except curatively treated basal cell or squamous cell carcinoma or cervical carcinoma\nDrug and/or alcohol abuse or dependence within the past 9 months\nBe serum positive for HIV, hepatitis B surface antigen, or viremic hepatitis C\nDocumented presence of a known Left Ventricular (LV) thrombus, aortic dissection, or aortic aneurysm. (Refer to \"Guidance to the PI\" section with regards to LV thrombus, below)\nBlood glucose levels (HbA1c) >10%\nSevere radiographic contrast allergy\nKnown history of anaphylactic reaction to penicillin or streptomycin\nHypersensitivity to dimethyl sulfoxide (DMSO)\nNon-cardiac condition with life expectancy < 1 year\nAcute stroke or transient ischemic attack within 3 months of enrollment\nBe pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods\nPacemaker-dependence with an Implantable Cardioverter Defibrillator (ICD) (Note: pacemaker-dependent candidates without an ICD are not excluded)\n\nPresence of a pacemaker and/or ICD generator with any of the following limitations/conditions:\n\nmanufactured before the year 2000\nleads implanted < 6 weeks prior to consent\nnon-transvenous epicardial or abandoned leads\nsubcutaneous ICDs\nleadless pacemakers\nA cardiac resynchronization therapy (CRT) device implanted less than 3 months prior to consent\nOther MRI contraindications (e.g. subject body habitus incompatible with MRI)\nNeed for advanced heart failure therapy (e.g. IV inotropes)\nBe currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial\nAny other condition that in the judgment of the Investigator would be a contraindication to enrollment or follow-up",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "80 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Shelly L Sayre, MPH",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "713-500-9529",
            "CentralContactEMail": "Shelly.L.Sayre@uth.tmc.edu"
          },
          {
            "CentralContactName": "Yvenie Desire",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "305-243-7273",
            "CentralContactEMail": "ydesire@miami.edu"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Joshua Hare, MD",
            "OverallOfficialAffiliation": "University of Miami",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Stanford University",
            "LocationStatus": "Recruiting",
            "LocationCity": "Stanford",
            "LocationState": "California",
            "LocationZip": "94304",
            "LocationCountry": "United States",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Fouzia Khan, MBBS",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "650-736-1410",
                  "LocationContactEMail": "fouziak@stanford.edu"
                },
                {
                  "LocationContactName": "Ashwini Narayana",
                  "LocationContactRole": "Contact",
                  "LocationContactEMail": "ashwinil@stanford.edu"
                },
                {
                  "LocationContactName": "Phil Yang, MD",
                  "LocationContactRole": "Principal Investigator"
                }
              ]
            }
          },
          {
            "LocationFacility": "University of Miami Miller School of Medicine",
            "LocationStatus": "Recruiting",
            "LocationCity": "Miami",
            "LocationState": "Florida",
            "LocationZip": "33136",
            "LocationCountry": "United States",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Lina Caceres",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "305-243-5399",
                  "LocationContactEMail": "lvc25@med.miami.edu"
                },
                {
                  "LocationContactName": "Jairo Tovar",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "305-243-5399",
                  "LocationContactEMail": "jat243@med.miami.edu"
                },
                {
                  "LocationContactName": "Josh Hare, MD",
                  "LocationContactRole": "Principal Investigator"
                }
              ]
            }
          },
          {
            "LocationFacility": "University of Louisville",
            "LocationStatus": "Recruiting",
            "LocationCity": "Louisville",
            "LocationState": "Kentucky",
            "LocationZip": "40202",
            "LocationCountry": "United States",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Heidi Wilson",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "502-540-3721",
                  "LocationContactEMail": "heidi.wilson@louisville.edu"
                },
                {
                  "LocationContactName": "Julie Caswell",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "502-587-4177",
                  "LocationContactEMail": "julie.caswell@louisville.edu"
                },
                {
                  "LocationContactName": "Roberto Bolli, MD",
                  "LocationContactRole": "Principal Investigator"
                }
              ]
            }
          },
          {
            "LocationFacility": "Texas Heart Institute",
            "LocationStatus": "Recruiting",
            "LocationCity": "Houston",
            "LocationState": "Texas",
            "LocationZip": "77030",
            "LocationCountry": "United States",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Nichole Piece",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "832-355-9173",
                  "LocationContactEMail": "npiece@texasheart.org"
                },
                {
                  "LocationContactName": "Sylvia Carranza",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "832-355-8524",
                  "LocationContactEMail": "SCarranza@texasheart.org"
                },
                {
                  "LocationContactName": "Emerson Perin, MD, PhD",
                  "LocationContactRole": "Principal Investigator"
                }
              ]
            }
          }
        ]
      }
    },
    "ReferencesModule": {
      "SeeAlsoLinkList": {
        "SeeAlsoLink": [
          {
            "SeeAlsoLinkLabel": "Cardiovascular Cell Therapy Research Network",
            "SeeAlsoLinkURL": "https://www.cctrn.org"
          },
          {
            "SeeAlsoLinkLabel": "Information on stem cells from the National Institutes of Health",
            "SeeAlsoLinkURL": "https://www.nih.gov/about-nih/what-we-do/nih-turning-discovery-into-health/stem-cells"
          },
          {
            "SeeAlsoLinkLabel": "DCM II Trial",
            "SeeAlsoLinkURL": "http://www.dcmii.org"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000009202",
            "ConditionMeshTerm": "Cardiomyopathies"
          },
          {
            "ConditionMeshId": "D000002311",
            "ConditionMeshTerm": "Cardiomyopathy, Dilated"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000006331",
            "ConditionAncestorTerm": "Heart Diseases"
          },
          {
            "ConditionAncestorId": "D000002318",
            "ConditionAncestorTerm": "Cardiovascular Diseases"
          },
          {
            "ConditionAncestorId": "D000006332",
            "ConditionAncestorTerm": "Cardiomegaly"
          },
          {
            "ConditionAncestorId": "D000083083",
            "ConditionAncestorTerm": "Laminopathies"
          },
          {
            "ConditionAncestorId": "D000030342",
            "ConditionAncestorTerm": "Genetic Diseases, Inborn"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M11306",
            "ConditionBrowseLeafName": "Cardiomyopathies",
            "ConditionBrowseLeafAsFound": "Cardiomyopathy",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M4719",
            "ConditionBrowseLeafName": "Cardiomyopathy, Dilated",
            "ConditionBrowseLeafAsFound": "Dilated Cardiomyopathy",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M8571",
            "ConditionBrowseLeafName": "Heart Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8572",
            "ConditionBrowseLeafName": "Cardiomegaly",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M2393",
            "ConditionBrowseLeafName": "Laminopathies",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M22839",
            "ConditionBrowseLeafName": "Genetic Diseases, Inborn",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T1876",
            "ConditionBrowseLeafName": "Dilated Cardiomyopathy",
            "ConditionBrowseLeafAsFound": "Dilated Cardiomyopathy",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC14",
            "ConditionBrowseBranchName": "Heart and Blood Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC16",
            "ConditionBrowseBranchName": "Diseases and Abnormalities at or Before Birth"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M85407",
            "InterventionBrowseLeafName": "Plasma-lyte 148",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M8814",
            "InterventionBrowseLeafName": "Altretamine",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "PhSol",
            "InterventionBrowseBranchName": "Pharmaceutical Solutions"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          },
          {
            "InterventionBrowseBranchAbbrev": "ANeo",
            "InterventionBrowseBranchName": "Antineoplastic Agents"
          }
        ]
      }
    }
  }
}